NCT07038005View on ClinicalTrials.gov

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

July 13, 2025

Primary Completion Date

September 22, 2026

Study Completion Date

June 8, 2027

Conditions
Advanced Malignant Tumors
Interventions
DRUG

SPGL008

Biological product

All Listed Sponsors
collaborator

Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd.

UNKNOWN

lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY